- Home
- XAIR vs VYNE Comparison
XAIR vs VYNE Comparison
Compare XAIR & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | VYNE |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 12.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | XAIR | VYNE |
|---|---|---|
| Price | $1.21 | $0.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | ★ 22.5M | 528.5K |
| Earning Date | 02-13-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,802,000.00 | $524,000.00 |
| Revenue This Year | $127.85 | N/A |
| Revenue Next Year | $179.78 | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.74 | 6.29 |
| 52 Week Low | $0.67 | $0.28 |
| 52 Week High | $10.40 | $2.94 |
Technical Indicators
Market Signals| Indicator | XAIR | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 58.21 |
| Support Level | $1.43 | $0.56 |
| Resistance Level | $2.26 | $0.57 |
| Average True Range (ATR) | 0.33 | 0.02 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 20.53 | 39.90 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.